

## Our promise

What our customers can expect from us is expressed in our core promise.

## Quality

### Driving Quality to the next level

Our proprietary enzymatic technology, along with our world-class, high quality active pharmaceutical ingredients and finished dosage forms deliver tangible value to customers, in terms of high purity, use efficiency and our favourable storage parameters.

## Reliability


### Our promise delivered

With over 75 years of experience in antibiotics, we are a well-established trusted business partner. We produce our key intermediates in-house. Our global backward integrated manufacturing setup safeguards security of supply for our customers.

## Sustainability

### Leading the way

Sustainability is at the heart of everything we do. We are an industry leader in the fight against antimicrobial resistance, actively working to minimise the release of our antibiotic residues into the environment. We work alongside partners such as the AMR Industry Alliance to encourage other manufacturers and supply chain partners to do the same.



## About Centrient Pharmaceuticals

Centrient Pharmaceuticals is the leading manufacturer of beta-lactam antibiotics, and a provider of next generation statins and anti-fungals. As a business-to-business partner we produce and sell intermediates, active pharmaceutical ingredients and finished dosage forms. We stand proudly at the centre of modern healthcare, as a maker of essential and life-saving medicines.

With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our 2700 employees work continuously to meet our customers' needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance.

Founded 150 years ago as the 'Nederlandsche Gist- en Spiritusfabriek', our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rotterdam (the Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, Egypt, the United States and Mexico. Centrient Pharmaceuticals is wholly owned by Bain Capital Private Equity, a leading global private investment firm.

## Contact and information

For more information, please visit [centrient.com](http://centrient.com) or email [licensing@centrient.com](mailto:licensing@centrient.com)

Copyright © 2019 Centrient Pharmaceuticals. All rights reserved.

Although all reasonable and diligent care has been used to ensure that the information provided herein is accurate, nothing contained herein shall, or may, be construed to imply any representation or warranty as to the accuracy, currency or completeness of this information nor shall it be construed to imply any other representation or warranty of any kind, including the implied warranties of merchantability, fitness for a particular purpose or non-infringement. Centrient has no obligation to update the statements contained in this presentation, unless required by applicable law. The content of this document is subject to change without any notice. Product offers are explicitly not made in respect of those jurisdictions where valid third party patent rights related to such products are in force. In such jurisdictions the advertised products are only offered for regulatory purposes insofar allowed under local provisions such as the Bolar provisions in the US and 2004/27/EC in Europe.  
VGL0022019



## Finished Dosage Forms Portfolio



# Why work with Centrient Pharmaceuticals?



## Our Finished Dosage Forms Portfolio

Molecule	Dosage form	Strength	EU-CTD*	Climatic Zone IV
<b>Beta-lactam Antibiotics</b>				
Amoxicillin	Hard capsule	250 mg 500 mg	✓	-
	Tablet (Dispersible)	500 mg 750 mg 1,000 mg	✓	-
	Powder for oral suspension	125 mg / 5 ml 250 mg / 5 ml 500 mg / 5 ml	✓	-
Amoxicillin + Clavulanic acid	Film-coated tablet	250 mg + 125 mg (2:1) 500 mg + 125 mg (4:1) 875 mg + 125 mg (7:1)	✓	ongoing
		500 mg + 62.5 mg (8:1)		-
	Powder for oral suspension	125 mg + 31.25 mg (4:1) / 5ml 250 mg + 62.5 mg (4:1) / 5ml 400 mg + 57 mg (7:1) / 5ml 600 mg + 42.9 mg (14:1) / 5ml	✓	✓
		200 mg + 28.5 mg (7:1) / 5ml		under development
Powder for oral suspension in sachet	500 mg + 125 mg (4:1) 875 mg + 125 mg (7:1) 1,000 mg + 125 mg (8:1)	✓	-	
<b>Statins</b>				
Atorvastatin	Film-coated tablet	10 mg   20 mg   40 mg   80 mg	✓	ongoing
		30mg   60mg	✓	-
Rosuvastatin	Film-coated tablet	5 mg   10 mg   20 mg   40 mg	✓	✓
		15mg   30mg	under development	-
<b>Anti-Fungals</b>				
Caspofungin	Powder concentrate for infusion solution	50 mg   70 mg	✓	NA – Cold Chain

\*Dossiers available for world-wide filing. Availability of dossiers is dependent on local regulatory requirements

### Your success is our success

What sets Centrient Pharmaceuticals apart is that we are a pure business-to-business provider of generic finished dosage forms, not marketing the products ourselves and therefore not competing with our customers in the end market. All our dossiers are ready available for out-licensing to our partners world-wide.

### European-based production facilities and supply chain

We work primarily with European-based finished dosage forms manufacturers. Customers can be confident that the origin, traceability and quality of our products are impeccable.

### Proactive QA, RA and artwork services

With our extensive regulatory and quality assurance know-how and services, doing business with us enables you to focus on what truly counts: your business and your customers.

### Reliable supply chain via backward integration

We provide intermediates, active pharmaceutical ingredients (APIs) and finished dosage forms based on our backward integrated global manufacturing capabilities. As a member of the Pharmaceutical Supply Chain Initiative, we ensure our supply chain is of the highest standards.

### Leading the way in responsible production

We operate dedicated wastewater treatments plants 24/7/365 at our manufacturing sites and apply antimicrobial activity testing to ensure disposed water is clean.

### PureActives® – the enzymatic difference

Our patented enzymatic platform completely replaces the traditional 13-step antibiotic production process with natural processes that eliminate the use of solvents or other chemicals. As well, the majority of the chemical steps in producing our statins have been replaced with enzymatic processes.